Paid Clinical Trials Fairbanks
Discover 36 paid clinical trials in Fairbanks, Alaska. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04164082
Conditions
Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Cystoscopy
Gemcitabine Hydrochloride
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated GlioblastomaTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT02201992
Conditions
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Observation
Crizotinib
Laboratory Biomarker Analysis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST TrialTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04267848
Conditions
Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Squamous Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Carboplatin
Cisplatin
Computed Tomography
Echocardiography
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsCognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Sponsor:
NRG Oncology
Location:
Code:
NCT05896189
Conditions
Breast Cancer
Cognitive Impairments
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Arm 1: Computerized Cognitive Training-Global Stimulation Games
Arm 2: Computerized Cognitive Training-Neuroplasticity Games
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaLenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT03937635
Conditions
Smoldering Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Daratumumab
Dexamethasone
Lenalidomide
Quality-of-Life Assessment
Questionnaire Administration
Intravesical BCG vs GEMDOCE in NMIBCIntravesical BCG vs GEMDOCE in NMIBC
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT05538663
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Gemcitabine
Docetaxel
Bacillus Calmette Guerin
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialT-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT04457596
Conditions
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Trastuzumab Emtansine
Placebo Administration
Tucatinib
Questionnaire Administration
Quality-of-Life Assessment